Annals of Oncology Advance Access published online on March 9, 2007
Annals of Oncology, doi:10.1093/annonc/mdm061
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2007 European Society for Medical Oncology
Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone
1 Department of Clinical and Biological Sciences, Thoracic Oncology Unit, San Luigi Hospital, University of Turin, Orbassano, Turin
2 National Cancer Research Institute, Genoa
3 Division of Medical Oncology, S. Giovanni Battista Hospital, Torino
4 Division of Medical Oncology, Novara
5 Division of Respiratory Diseases, Borgo Trento Hospital, Verona
6 Division of Respiratory Diseases, Ospedali Riuniti, Varese
7 Division of Respiratory Diseases, Ospedale di Circolo, Varese
8 Division of Respiratory Diseases, Mariano Santo Hospital, Cosenza
9 Division of Respiratory Diseases, Cervello Hospital, Palermo
10 Division of Medical Oncology, IRCC Candiolo, Torino
11 Division of Medical Oncology, Ospedale Civile, Ancona
12 Division of Medical Oncology, Silvestrini Hospital, Perugia, Italy
* Correspondence to: Dr S. Novello, University of Turin, Department of Clinical and Biological Sciences, Thoracic Oncology Unit, San Luigi Hospital, Regione Gonzole 10, 10043 Orbassano, Torino, Italy. Tel: +39-011-9026-978; Fax: +39-011-9038-616; E-mail: silvia.novello{at}unito.it
Background: This randomised phase III study investigated if in responsive and stable disease (SD) stage IV patients after two courses of cisplatin and gemcitabine, single-agent gemcitabine (experimental arm) was not inferior in terms of overall survival (OS) to cisplatin–gemcitabine (standard arm).
Patients and methods: Noninferiority was defined as an increase in the hazard of death (HR) 
1.33 in the experimental arm. From January 2001 to February 2004, 340 patients were registered and 250 were randomised. Cisplatin was administered on day 1 at 75 mg/m2 and Gemcitabine on days 1 and 8 at 1250 mg/m2 every 3 weeks.
Results: Response rate after two courses was 29%. The 1-year progression-free survival was 13% in both arms. One-year survival was 52% in the standard and 42% in the experimental arm for an HR of 1.21 [90% confidence interval (CI) 0.97–1.51]. Postprogression survival was in favour of the standard arm (HR 1.30, 95% CI 0.99–1.70, P = 0.051). Grades 3–4 toxicity favoured in the experimental arm.
Conclusion: In responsive and SD patients with stage IV non-small-cell lung cancer it was not possible to demonstrate that three courses of gemcitabine alone are not inferior, in terms of OS, to the standard approach of three courses of cisplatin–gemcitabine.
chemotherapy, cisplatin, gemcitabine, metastatic disease, non-small-cell lung cancer
Received for publication October 26, 2006. Revision received January 22, 2007. Accepted for publication January 23, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J-P. Sculier and D. Moro-Sibilot First- and second-line therapy for advanced nonsmall cell lung cancer Eur. Respir. J., April 1, 2009; 33(4): 915 - 930. [Abstract] [Full Text] [PDF]
|
|